Special Issue

Extracellular Vesicles for Diagnosis and Therapy of Human Diseases, 2nd Edition

Message from the Guest Editor

Within the last decade, extracellular vesicles (EVs) have been recognized as a novel mechanism of intra- and intercellular communication, delivering bioactive molecules primarily composed of proteins, metabolites, and nucleic acids, including messenger RNAs (mRNAs) and microRNAs (miRNAs). EVs are also found in biological fluids such as blood, saliva, cerebrospinal fluid, and urine. They can play a role in different pathogeneses and could contain biomarkers linked to specific human diseases. Moreover, the specific biological activity of EVs has presented potential benefits for the correction of cellular dysfunction. Consequently, EVs can be used as ideal vectors for biodelivery, specifically for drug delivery in clinical applications. However, in order to use EVs for the diagnosis and treatment of human diseases, it is important to develop appropriate methods for their isolation as well as to investigate the molecular composition, functionality, and distribution of EV cargo. The purpose of this Special Issue is to publish work related to all aspects of *EVs* for the diagnosis and treatment of human diseases.

Guest Editor

Dr. Zoran Minic

Department of Chemistry and Biomolecular Sciences, John L. Holmes Mass Spectrometry Facility, Faculty of Science, University of Ottawa, Ottawa, ON K1N6N5, Canada

Deadline for manuscript submissions

31 July 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed

mdpi.com/si/264159

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).